文献速递肝病消化道肿瘤与早癌

CXCL12+肿瘤相关内皮细胞促进肝细胞癌免疫抵抗

CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2024-10-09

本研究采用多组学策略分析肝细胞癌肿瘤微环境中肿瘤相关内皮细胞的单细胞与时空演化,鉴定出CXCL12+内皮细胞亚群通过分泌CXCL12阻碍CD8+初始T细胞向细胞毒性T细胞分化并招募髓源性抑制细胞。靶向CXCL12与PD1的双特异性抗体在人源化小鼠模型中增强抗肿瘤免疫反应。

要点

  • 鉴定出肝细胞癌中CXCL12+肿瘤相关内皮细胞新亚群,在免疫抑制中起关键作用。
  • CXCL12+内皮细胞通过分泌CXCL12阻碍CD8+初始T细胞分化为CD8+细胞毒性T细胞。
  • 靶向CXCL12和PD1的双特异性抗体在人源化小鼠肝细胞癌模型中增强免疫反应。

核心结论

  • CXCL12+肿瘤相关内皮细胞在肝细胞癌微环境免疫抑制中起关键作用,靶向该亚群是增强肝细胞癌免疫治疗疗效的有前景策略。

研究设计与样本

  • 采用多组学分析策略研究肝细胞癌肿瘤微环境中肿瘤相关内皮细胞的单细胞与时空演化,并分析肝细胞癌临床队列中内皮细胞亚群与免疫治疗结局的相关性。
  • 通过体外和体内研究确认内皮细胞亚群对免疫微环境的影响,并使用内皮细胞亚群特异性敲除小鼠模型及人源化小鼠模型探索机制。

主要发现

  • 鉴定出CXCL12+肿瘤相关内皮细胞新亚群,在肝细胞癌肿瘤微环境中发挥免疫抑制作用。
  • CXCL12+肿瘤相关内皮细胞通过分泌CXCL12阻碍CD8+初始T细胞向CD8+细胞毒性T细胞分化,并招募髓源性抑制细胞。
  • 靶向CXCL12和PD1的双特异性抗体在人源化小鼠肝细胞癌模型中增强抗肿瘤免疫反应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The tumor microenvironment (TME) plays a crucial role in the limited efficacy of existing treatments for hepatocellular carcinoma (HCC), with tumor-associated endothelial cells (TECs) serving as fundamental TME components that substantially influence tumor progression and treatment efficacy. However, the precise roles and mechanisms of TECs in HCC remain inadequately understood. METHODS: We employed a multi-omics profiling strategy to investigate the single-cell and spatiotemporal evolution of TECs within the microenvironment of HCC tumors, showcasing varied responses to immunotherapy. Through an analysis of a clinical cohort of patients with HCC, we explored the correlation between TEC subpopulations and immunotherapy outcomes. The influence of TEC subsets on the immune microenvironment was confirmed through comprehensive in vitro and in vivo studies. To further explore the mechanisms of distinct TEC subpopulations in microenvironmental modulation and their impact on immunotherapy, we utilized TEC subset-specific knockout mouse models as well as humanized mouse models. RESULTS: In this study, we identified a new subset of CXCL12+ TECs that exert a crucial role in immune suppression within the HCC TME. Functionally, CXCL12+ TECs impede the differentiation of CD8+ naïve T cells into CD8+ cytotoxic T cells by secreting CXCL12. Furthermore, they attract myeloid-derived suppressor cells (MDSCs). A bispecific antibody was developed to target both CXCL12 and PD1 specifically, showing significant promise in bolstering anti-tumor immune responses and advancing HCC therapy. CONCLUSIONS: CXCL12+ TECs are pivotal in mediating immunosuppression within the HCC microenvironment and targeting CXCL12+ TECs presents a promising approach to augment the efficacy of immunotherapies in patients with HCC. IMPACT AND IMPLICATIONS: This investigation reveals a pivotal mechanism wherein CXCL12+ tumor-associated endothelial cells (TECs) emerge as crucial modulators of immune suppression in the tumor microenvironment of hepatocellular carcinoma (HCC). The discovery of CXCL12+ TECs as inhibitors of CD8+ naïve T cell activation and recruiters of myeloid-derived suppressor cells significantly advances our grasp of the dynamic between HCC and immune regulation. Moreover, the development and application of a bispecific antibody precisely targeting CXCL12 and PD1 has proven to enhance immune responses in a humanized mouse HCC model. This finding underscores a promising therapeutic direction for HCC, offering the potential to amplify the impact of current immunotherapies.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lu Y, Liu Y, Zuo X, et al. CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma. J Hepatol. 2024. PMID: 39393439. doi:10.1016/j.jhep.2024.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。